BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 36157535)

  • 1. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis.
    Risaliti M; Bartolini I; Campani C; Arena U; Xodo C; Adotti V; Rosi M; Taddei A; Muiesan P; Amedei A; Batignani G; Marra F
    World J Gastroenterol; 2022 Aug; 28(29):3981-3993. PubMed ID: 36157535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Adjuvant Transarterial Chemoembolization after Radical Hepatectomy in Solitary Hepatocellular Carcinoma Patients: A Retrospective Study.
    Zeng G; Zou B; Li Y; Lin E; Liu X; Li P; Chen J; Zhang B; Jia Y; Cai C; Li J
    J Invest Surg; 2022 Jun; 35(6):1208-1216. PubMed ID: 35078386
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis.
    Zhu SL; Ke Y; Peng YC; Ma L; Li H; Li LQ; Zhong JH
    PLoS One; 2014; 9(12):e115834. PubMed ID: 25541684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
    Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
    Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma.
    Chen S; Jin H; Dai Z; Wei M; Xiao H; Su T; Li B; Liu X; Wang Y; Li J; Shen S; Zhou Q; Peng B; Peng Z; Peng S
    Cancer Med; 2019 Apr; 8(4):1530-1539. PubMed ID: 30864247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China.
    Wu Z; Cui L; Qian J; Luo L; Tu S; Cheng F; Yuan L; Zhang W; Lin W; Tang H; Li X; Li H; Zhang Y; Zhu J; Li Y; Xiong Y; Hu Z; Peng P; He Y; Liu L; He K; Shen W
    BMC Cancer; 2023 Apr; 23(1):325. PubMed ID: 37029339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis.
    Bogdanovic A; Bulajic P; Masulovic D; Bidzic N; Zivanovic M; Galun D
    Sci Rep; 2021 Feb; 11(1):4493. PubMed ID: 33627697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study.
    Wang L; Lin N; Lin K; Xiao C; Wang R; Chen J; Zhou W; Liu J
    J Gastrointest Surg; 2021 May; 25(5):1172-1183. PubMed ID: 32440804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study.
    Zhong C; Zhang YF; Huang JH; Xiong CM; Wang ZY; Chen QL; Guo RP
    BMC Cancer; 2018 Jun; 18(1):643. PubMed ID: 29879928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study.
    Chen J; Lai L; Lin Q; Huang W; Cai M; Zhu K; Huang M
    Oncotarget; 2017 Jan; 8(1):408-417. PubMed ID: 27880724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
    Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
    Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
    Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
    Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
    World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
    Kim JY; Sinn DH; Gwak GY; Choi GS; Saleh AM; Joh JW; Cho SK; Shin SW; Carriere KC; Ahn JH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Mol Hepatol; 2016 Jun; 22(2):250-8. PubMed ID: 27377909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis.
    Yang Y; Lin K; Liu L; Qian Y; Yang Y; Yuan S; Zhu P; Huang J; Liu F; Gu F; Fu S; Jiang B; Liu H; Pan Z; Lau WY; Zhou W
    Cancer Med; 2021 Mar; 10(6):2100-2111. PubMed ID: 33650288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study.
    Hu Z; Wang X; Fu Y; Yang D; Zhou Z; Chen M; Song X; Zhang Y
    Int J Surg; 2024 Feb; 110(2):1019-1027. PubMed ID: 38006301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.